Loss of C/EBPα and favorable prognosis of acute myeloid leukemias: A biological paradox

Journal of Clinical Oncology

Volumn 22, Issue 4, 2004, Pages 582-584

  Perrotti, Danilo ^a   Marcucci, Guido ^a   Caligiuri, Michael A ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; PROTEIN P21; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR RUNX1; CCAAT ENHANCER BINDING PROTEIN; DDIT3 PROTEIN, HUMAN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CELL SURVIVAL; DNA BINDING; DOWN REGULATION; EDITORIAL; EOSINOPHIL; GENE CLUSTER; GENE IDENTIFICATION; GENE MUTATION; HEMATOPOIETIC STEM CELL; LEUKEMOGENESIS; MONOCYTE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA TRANSLATION; TRANSCRIPTION REGULATION; DISEASE FREE SURVIVAL; GENETICS; HUMAN; MORTALITY; MUTATION; MYELOID LEUKEMIA; NOTE; SURVIVAL RATE;

CCAAT-ENHANCER-BINDING PROTEINS; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, MYELOID; MUTATION; SURVIVAL RATE; TRANSCRIPTION FACTOR CHOP; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 1442283221     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.12.965     Document Type: Editorial

References (34)

1. Tenen DG, Hromas R, Licht JD, et al: Transcription factors, normal myeloid development, and leukemia. Blood 90:489-519, 1997
2. Tenen DG: Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 3:89-101, 2003
3. Zhang DE, Zhang P, Wang ND, et al: Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci U S A 94:569-574, 1997
4. Radomska HS, Huettner CS, Zhang P, et al: CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 18:4301-4314, 1998
5. Cammenga J, Mulloy JC, Berguido FJ, et al: Induction of C/EBPalpha activity alters gene expression and differentiation of human CD34+ cells. Blood 101:2206-2214, 2003
6. Keeshan K, Santilli G, Corradini F, et al: Transcription activation function of C/EBPalpha is required for induction of granulocytic differentiation. Blood 102:1267-1275, 2003
7. D'Alo' F, Johansen LM, Nelson EA, et al: The amino terminal and E2F interaction domains are critical for C/EBP alpha-mediated induction of granulopoietic development of hematopoietic cells. Blood 102:3163-3171, 2003
8. Wang QF, Cleaves R, Kummalue T, et al: Cell cycle inhibition mediated by the outer surface of the C/EBPalpha basic region is required but not sufficient for granulopoiesis. Oncogene 22:2548-2557, 2003
9. Johansen LM, Iwama A, Lodie TA, et al: c-Myc is a critical target for C/EBPalpha in granulopoiesis. Mol Cell Biol 21:3789-3806, 2001
10. Porse BT, Pedersen TA, Xu X, et al: E2F repression by C/EBPalpha is required for adipogenesis and granulopoiesis in vivo. Cell 107:247-258, 2001
11. Pabst T, Mueller BU, Zhang P, et al: Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 27:263-270, 2001
12. Gombart AF, Hofmann WK, Kawano S, et al: Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 99:1332-1340, 2002
13. Snaddon J, Smith ML, Neat M, et al: Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2. Genes Chromosomes Cancer 37:72-78, 2003
14. van Waalwijk van Doorn-Khosrovani SB, Erpelinck C, et al: Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J 4:31-40, 2003
15. Fröhling S, Schlenk RF, Stolze I, et al: CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22:624-633, 2004
16. Preudhomme C, Sagot C, Boissel N, et al: Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: A study from the Acute Leukemia French Association (ALFA). Blood 100:2717-2723, 2002
17. Grimwade D, Walker H, Oliver F, et al: The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial - The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92:2322-2333, 1998
18. Baldus CD, Tanner SM, Ruppert AS, et al: BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: A Cancer and Leukemia Group B Study. Blood 102:1613-1618, 2003
19. Caligiuri MA, Strout MP, Lawrence D, et al: Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 58:55-5, 1998
20. Whitman SP, Archer KJ, Feng L, et al: Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer And Leukemia Group B study. Cancer Res 61:7233-7239, 2001
21. Zheng R, Friedman AD, Small D: Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations. Blood 100:4154-1161, 2002
22. Zheng R, Friedman AD, Levis M, et al: Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBP{alpha} expression. Blood 2003 Oct 30 [Epub ahead of print]
23. Basseres D, Radomska HS, Yamamoto Y, et al: Differentiation block in FLT3 Mutant AML by inactivation of C/EBPa function by phosphorylation. Blood 102:17, 2003 (abstr 599)
24. Marcucci G, Caligiuri MA, Bloomfield CD: Molecular and clinical advances in core binding factor primary acute myeloid leukemia: A paradigm for translational research in malignant hematology. Cancer Invest 18:768-780, 2000
25. Pabst T, Mueller BU, Harakawa N, et al: AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med 7:444-151, 2001
26. Westendorf JJ, Yamamoto CM, Lenny N, et al: The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol 18:322-333, 1998
27. Tenen DG: Abnormalities of the CEBP alpha transcription factor: A major target in acute myeloid leukemia. Leukemia 15:688-689, 2001
28. Truong BT, Lee YJ, Lodie TA, et al: CCAAT/enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia. Blood 101: 1141-1148, 2003
29. Cilloni D, Carturan S, Gottardi E, et al: Down-modulation of the C/EBPalpha transcription factor in core binding factor acute myeloid leukemias. Blood 102:2705-2706, 2003
30. Bloomfield CD. Lawrence D, Byrd JC, et al: Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58:4173-4179, 1998
31. Perrotti D, Cesi V, Trotta R, et al: BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat Genet 30:48-58, 2002
32. Wagner K, Rosenbauer F, Zhang P, et al: Disruption of the C/EBPa gene leads to an immature phenotype of a BCR/ABL-induced myeloproliferative disease in a murine transplant model. Blood 102:584, 2003 (abstr 2152)
33. Timchenko LT, Iakova P, Welm AL, et al: Calreticulin interacts with C/EBPalpha and C/EBPbeta mRNAs and represses translation of C/EBP proteins. Mol Cell Biol 22:7242-57, 2002
34. Helbling D, Mueller B, Timchenko NA, et al: The myeloid transcription factor C/EBPa is a key target gene of the leukaemia fusion gene AML1/MDS1/EVI1. Blood, 102:846, 2003 (abstr 3144)